Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 30, 2015 4:24 PM ET

Pharmaceuticals

Company Overview of Phibro Animal Health Corporation

Company Overview

Phibro Animal Health Corporation operates as a diversified developer, manufacturer, and marketer of a range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy, and aquaculture. It also sells specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment offers antibacterials, anticoccidials, and vaccines, which help prevent and manage infectious diseases in livestock and enhance food safety; and nutritional specialty products, which aid the continued he...

300 Frank West Burr Boulevard

Glenpointe Centre East

3rd Floor

Suite 21

Teaneck, NJ 07666

United States

1,100 Employees

Phone:

201-329-7300

Fax:

201-329-7399

Key Executives for Phibro Animal Health Corporation

Chairman, Chief Executive Officer, President, Member of Compensation Committee and Member of Retirement Benefits Committee
Age: 67
Total Annual Compensation: $3.0M
Chief Operating Officer and Director
Age: 70
Total Annual Compensation: $914.7K
President of Animal Health
Age: 50
Total Annual Compensation: $708.5K
Compensation as of Fiscal Year 2014.

Phibro Animal Health Corporation Key Developments

Phibro Animal Health Corporation Announces Unaudited Consolidated Earnings Results for Fourth Quarter and Full Year Ended Dec. 31, 2014

Phibro Animal Health Corporation announced unaudited consolidated earnings results for fourth quarter and full year ended Dec. 31, 2014. For the quarter, the company reported net sales of $188.7 million, operating income of $19.8 million, income before income taxes of $17.3 million, net income of $15.4 million or $0.39 per diluted share, adjusted EBITDA of $25 million, adjusted net income of $14.1 million or $0.33 per diluted share, net cash provided by operating activities of $8.4 million compared to the net sales of $172.7 million, operating income of $17 million, income before income taxes of $7.1 million, net income of $2.3 million or $0.08 per diluted share, adjusted EBITDA of $22.3 million, adjusted net income of $13.6 million or $0.34 per diluted share, net cash provided by operating activities of $16.6 million for the same quarter a year ago. Net sales increased $15.9 million, or 9%, as compared to the three months ended December 31, 2013, due to growth in Animal Health and Mineral Nutrition of $10.8 million and $8.1 million, respectively, offset by declines in Performance Products of $3.0 million. For the year, the company reported net sales of $376.1 million, operating income of $44.9 million, income before income taxes of $40.1 million, net income of $35.9 million or $0.9 per diluted share, adjusted EBITDA of $55.5 million, adjusted net income of $34.4 million or $0.87 per diluted share, net cash provided by operating activities of $25.8 million compared to the net sales of $335 million, operating income of $33.4 million, income before income taxes of $14.1 million, net income of $8.1 million or $0.27 per diluted share, adjusted EBITDA of $43.9 million, adjusted net income of $25.3 million or $0.64 per diluted share, net cash provided by operating activities of $16.4 million for the previous year.

Phibro Animal Health Corporation Declares Quarterly Cash Dividend, Payable on March 25, 2015

Phibro Animal Health Corporation announced the declaration of a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on March 25, 2015, to stockholders of record at the close of business on March 4, 2015.

Phibro Animal Health Corporation Announces Licensing Agreement with Merial for Phibro's Vaccine Delivery Technology

Phibro Animal Health Corporation announced it has entered into a long-term global license arrangement with Merial SAS (Lyon, France) to share in the use of Phibro's vaccine delivery technology for use in animal vaccines. The agreement was signed in 2012 and is being announced following Merial's receipt of marketing authorization in France for an avian vaccine product utilizing the licensed technology. The patented technology utilizes an innovative effervescent tablet that contains a freeze-dried sterile vaccine virus, packaged in sealed aluminum blister packages. The technology replaces the glass vials that are in common use today, and offers major advantages in a number of areas including storage requirements, customer handling and disposal. Under the arrangement, use of the technology will be limited to Merial, Phibro and their affiliates.

Similar Private Companies By Industry

Company Name Region
Midway Food Animal Sciences United States
Shionogi USA, Inc. United States
EvoGenix, Inc. United States
Matrivax Research & Development Corp. United States
Drais Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 22, 2015
MJ Biologics, Inc., Certain Assets
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Phibro Animal Health Corporation, please visit www.pahc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.